263 related articles for article (PubMed ID: 31692250)
41. Ovarian Insufficiency is Major Short-term Toxicity in Systemic Lupus Erythematosus Patients Treated with Cyclophosphamide.
Singh G; Misra R; Aggarwal A
J Assoc Physicians India; 2016 Feb; 64(2):28-31. PubMed ID: 27730777
[TBL] [Abstract][Full Text] [Related]
42. Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.
Rondaan C; van Leer CC; van Assen S; Bootsma H; de Leeuw K; Arends S; Bos NA; Westra J
Lupus; 2018 Jul; 27(8):1271-1278. PubMed ID: 29667858
[TBL] [Abstract][Full Text] [Related]
43. Synergistic effect of cumulative corticosteroid dose and immunosuppressants on avascular necrosis in patients with systemic lupus erythematosus.
Kwon HH; Bang SY; Won S; Park Y; Yi JH; Joo YB; Lee HS; Bae SC
Lupus; 2018 Sep; 27(10):1644-1651. PubMed ID: 29950160
[TBL] [Abstract][Full Text] [Related]
44. Malignancy in Systemic Lupus Erythematosus (SLE) Patients.
Cader RA; Mei Yee AK; Yassin A; Ahmad I; Haron SN
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3551-3555. PubMed ID: 30583682
[TBL] [Abstract][Full Text] [Related]
45. Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report.
Habuka M; Wada Y; Kurosawa Y; Yamamoto S; Tani Y; Ohashi R; Ajioka Y; Nakano M; Narita I
BMC Res Notes; 2018 Mar; 11(1):165. PubMed ID: 29506558
[TBL] [Abstract][Full Text] [Related]
46. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus.
Pryor BD; Bologna SG; Kahl LE
Arthritis Rheum; 1996 Sep; 39(9):1475-82. PubMed ID: 8814058
[TBL] [Abstract][Full Text] [Related]
47. Comorbidities of systemic lupus erythematosus prior to and following diagnosis in different age-at-onset groups.
Yu CY; Kuo CF; Chou IJ; Chen JS; Lu HY; Wu CY; Chen LC; Huang JL; Yeh KW
Lupus; 2022 Jul; 31(8):963-973. PubMed ID: 35536913
[TBL] [Abstract][Full Text] [Related]
48. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study.
Tselios K; Gladman DD; Su J; Urowitz MB
J Rheumatol; 2016 Mar; 43(3):552-8. PubMed ID: 26773121
[TBL] [Abstract][Full Text] [Related]
49. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination.
Yun H; Yang S; Chen L; Xie F; Winthrop K; Baddley JW; Saag KG; Singh J; Curtis JR
Arthritis Rheumatol; 2016 Sep; 68(9):2328-37. PubMed ID: 26990731
[TBL] [Abstract][Full Text] [Related]
50. [A multicenter study on the tolerance of intravenous low-dose cyclophosphamide in systemic lupus erythematosus].
Shao M; Guo HF; Lei LY; Zhao Q; Ding YJ; Lin J; Wu R; Yu F; Li YC; Miao HL; Zhang LY; DU Y; Jiao RY; Pang LX; Long L; Li ZG; Li R
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1112-1116. PubMed ID: 36533341
[TBL] [Abstract][Full Text] [Related]
51. Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study.
Merayo-Chalico J; Gómez-Martín D; Piñeirúa-Menéndez A; Santana-De Anda K; Alcocer-Varela J
QJM; 2013 May; 106(5):451-7. PubMed ID: 23458779
[TBL] [Abstract][Full Text] [Related]
52. Exploring the risk factors for ischemic cerebrovascular disease in systemic lupus erythematosus: A single-center case-control study.
Su L; Qi Z; Guan S; Wei L; Zhao Y
Front Immunol; 2022; 13():978910. PubMed ID: 36238309
[TBL] [Abstract][Full Text] [Related]
53. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
54. Herpes zoster in patients with systemic lupus erythematosus: Clinical features, complications and risk factors.
Chen D; Li H; Xie J; Zhan Z; Liang L; Yang X
Exp Ther Med; 2017 Dec; 14(6):6222-6228. PubMed ID: 29285180
[TBL] [Abstract][Full Text] [Related]
55. Infections in Systemic Lupus Erythematosus.
Rajadhyaksha AG; Jobanputra K
J Assoc Physicians India; 2020 May; 68(5):18-21. PubMed ID: 32610860
[TBL] [Abstract][Full Text] [Related]
56. Experience with mycophenolate mofetil as maintenance therapy in five pediatric patients with severe systemic lupus erythematosus.
Dittrich K; Ross S; Benz K; Amann K; Dötsch J
Klin Padiatr; 2009 Dec; 221(7):425-9. PubMed ID: 20013565
[TBL] [Abstract][Full Text] [Related]
57. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
[TBL] [Abstract][Full Text] [Related]
58. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Mok CC
Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
[TBL] [Abstract][Full Text] [Related]
59. [The efficacy of mycophenolate mofetil for systemic lupus erythematosus].
Suzuki D; Ogawa N; Sawada J; Kimoto O; Shimoyama K; Hayashi H
Nihon Rinsho Meneki Gakkai Kaishi; 2009 Aug; 32(4):263-8. PubMed ID: 19721347
[TBL] [Abstract][Full Text] [Related]
60. Severe multiorganic flare of systemic lupus erythematosus successfully treated with rituximab and cyclophosphamide avoiding high doses of prednisone.
Gonzalez-Echavarri C; Pernas B; Ugarte A; Ruiz-Irastorza G
Lupus; 2014 Mar; 23(3):323-6. PubMed ID: 24531426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
